Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1172889 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29762987 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL11330106 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL30296418 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL6352272 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL867188 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10840673 | 0.82 | — | — | |
| SCHEMBL12468765 | 0.82 | — | — | |
| SCHEMBL68640 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL48670 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820309-A | Piperazinyl-heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-109988126-B | 3-amino-oxetane derivative and preparation method and application thereof | 南京富润凯德生物医药有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-114736204-A | Preparation method of pexidaltinib structural analogue and application of pexidaltinib structural analogue in tumor resistance | 湖北工业大学 | 2022-07-12 | — | — | CN | claimed |
| EP-3424911-B1 | POSACONAZOLE, COMPOSITION, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USES THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO LTD (CN) | 2021-07-28 | — | — | EP | claimed |
| US-10696643-B2 | Posaconazole, composition, intermediate, preparation method and use thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-06-30 | — | — | US | claimed |
| CN-109988126-A | A kind of 3- amino-oxetane derivative and its preparation method and application | 南京富润凯德生物医药有限公司 | 2019-07-09 | — | — | CN | claimed |
| US-20190071408-A1 | POSACONAZOLE, COMPOSITION, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USES THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2019-03-07 | — | — | US | claimed |
| EP-3424911-A1 | POSACONAZOLE, COMPOSITION, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USES THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2019-01-09 | — | — | EP | claimed |
| EP-2758385-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN LAB LTD (IN) | 2018-03-28 | — | — | EP | claimed |
| CN-106496220-A | A kind of preparation method of lysergol | 重庆乾泰生物医药有限公司 | 2017-03-15 | — | — | CN | claimed |
| CN-105294530-A | Purification method of vernakalant hydrochloride | MEDISANTECH CORP | 2016-02-03 | — | — | CN | claimed |
| US-9102664-B2 | Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | claimed |
| CN-104610121-A | Preparation method for Vernakalant hydrochloride | BEIJING HARBIN MEDISAN TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | claimed |
| WO-2015059716-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ((3S,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHYL-4-METHYLBENZENESULFONATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-04-30 | — | — | WO | claimed |
| US-20140343285-A1 | Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof | MSN LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | claimed |
| EP-2758385-A2 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN Laboratories Limited (IN) | 2014-07-30 | — | — | EP | claimed |
| CN-101939308-B | Preparation method of (3s,4s)-3-hexyl-4-((R)-2-hydroxytridecyl)-oxetan-2-one and product of that method | CHONGQING ZHIEN PHARMACEUTICAL CO LTD | 2013-10-23 | — | — | CN | claimed |
| WO-2013042138-A2 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN LABORATORIES LIMITED (IN) | 2013-03-28 | — | — | WO | claimed |
| CN-102977105-A | Synthesis method of 3(methyl),7-diazabicyclooctane | CGENE TECH SUZHOU CHINA CO LTD | 2013-03-20 | — | — | CN | claimed |
| WO-2012038975-A2 | PROCESS FOR THE PREPARATION OF (3ARS,12BRS)-5-CHLORO-2-METHYL-2,3,3A12B-TETRAHYDRO-1HDIBENZO[2,3:6,7] OXEPINO [4,5-C]PYRROLE MALEATE AND IT'S PHARMACEUTICAL COMPOSITION THEREOF | MSN LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | claimed |